Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGENĀ – Agenus Inc.

Float Short %

8.49

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

1.19

EPS Last/This Y

10.17

EPS This/Next Y

-1.55

Price

4.52

Target Price

12.33

Analyst Recom

2

Performance Q

19.26

Relative Volume

0.32

Beta

1.47

Ticker: AGEN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25AGEN5.950.530.0118715
2025-07-28AGEN6.350.500.1019636
2025-07-29AGEN5.880.490.1219730
2025-07-30AGEN5.910.510.2619932
2025-07-31AGEN5.490.510.0520002
2025-08-01AGEN5.340.510.3019969
2025-08-04AGEN5.390.510.1919998
2025-08-05AGEN5.30.500.9620124
2025-08-06AGEN4.760.510.3120386
2025-08-07AGEN4.750.530.0320249
2025-08-08AGEN4.80.490.1721410
2025-08-11AGEN4.270.480.0221656
2025-08-12AGEN4.820.410.0224248
2025-08-13AGEN4.530.370.0626410
2025-08-14AGEN4.530.370.0126059
2025-08-15AGEN4.620.350.5325716
2025-08-18AGEN4.530.140.0313830
2025-08-19AGEN4.540.140.0213958
2025-08-20AGEN4.510.140.2014083
2025-08-21AGEN4.590.140.0614132
2025-08-22AGEN4.540.140.0214173
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25AGEN5.96153.7163.91.90
2025-07-28AGEN6.41153.7168.31.90
2025-07-29AGEN5.88153.7161.11.90
2025-07-30AGEN5.90153.7164.81.90
2025-07-31AGEN5.52153.7161.41.90
2025-08-01AGEN5.36153.7163.51.90
2025-08-04AGEN5.40153.7164.81.90
2025-08-05AGEN5.29153.7163.51.90
2025-08-06AGEN4.75153.7160.01.90
2025-08-07AGEN4.76153.7164.51.90
2025-08-08AGEN4.80153.7164.91.90
2025-08-11AGEN4.27153.7159.51.90
2025-08-12AGEN4.82153.7170.01.90
2025-08-13AGEN4.54153.7155.51.90
2025-08-14AGEN4.54153.7109.51.90
2025-08-15AGEN4.62153.7109.6-0.95
2025-08-18AGEN4.54153.7109.2-0.95
2025-08-19AGEN4.53153.7109.4-0.95
2025-08-20AGEN4.51153.7109.4-0.95
2025-08-21AGEN4.57153.7109.6-0.95
2025-08-22AGEN4.52145.5109.3-0.42
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25AGEN0.0013.038.64
2025-07-28AGEN0.00-4.088.64
2025-07-29AGEN0.00-4.088.64
2025-07-30AGEN0.00-4.088.64
2025-07-31AGEN0.00-4.088.64
2025-08-01AGEN0.00-4.088.64
2025-08-04AGEN0.00-4.288.64
2025-08-05AGEN0.00-4.288.64
2025-08-06AGEN0.00-4.288.64
2025-08-07AGEN0.00-4.288.64
2025-08-08AGEN0.00-4.288.64
2025-08-11AGEN0.00-6.238.64
2025-08-12AGEN0.00-6.239.61
2025-08-13AGEN0.00-6.239.61
2025-08-14AGEN0.00-6.238.27
2025-08-15AGEN0.00-6.238.27
2025-08-18AGEN0.00-12.318.48
2025-08-19AGEN0.00-12.318.49
2025-08-20AGEN0.00-12.318.49
2025-08-21AGEN0.00-12.318.49
2025-08-22AGEN0.00-12.318.49
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-1

Avg. EPS Est. Current Quarter

1.4

Avg. EPS Est. Next Quarter

0.19

Insider Transactions

Institutional Transactions

-12.31

Beta

1.47

Average Sales Estimate Current Quarter

66

Average Sales Estimate Next Quarter

49

Fair Value

Quality Score

48

Growth Score

23

Sentiment Score

46

Actual DrawDown %

96.6

Max Drawdown 5-Year %

-98.8

Target Price

12.33

P/E

Forward P/E

PEG

P/S

1.42

P/B

P/Free Cash Flow

EPS

-7.15

Average EPS Est. Cur. Y​

-0.42

EPS Next Y. (Est.)

-1.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-162.9

Relative Volume

0.32

Return on Equity vs Sector %

22

Return on Equity vs Industry %

34.9

EPS 1 7Days Diff

-2.3

EPS 1 30Days Diff

-2.32

EBIT Estimation

109.3
Agenus Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 316
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
stock quote shares AGENĀ – Agenus Inc. Stock Price stock today
news today AGENĀ – Agenus Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AGENĀ – Agenus Inc. yahoo finance google finance
stock history AGENĀ – Agenus Inc. invest stock market
stock prices AGEN premarket after hours
ticker AGEN fair value insiders trading